Member Info for Cliostock

TC, as we were saying the other day, I desperately want to be on your side of this debate, but the track record is really hard to argue with. Sure, one can find confirmation bias, but do we really think Ashman has been working on this in time for a June release and not even hinted at it; he is the king of implication. I’d be over the moon, but I’ll have to see to believe, which is the way the rest of the market is treating us. I’d never say never, after all he did successfully change brokers after they acted with contempt towards SA/us, but that’s really the basics. I also think the acquisitions were a good idea and the funding was rectified quickly too. I just need to see him bringing some money in before I believe he can revolutionise some other aspect of skincare.

TC, I thought the other day that this wording in the Zenakine Launch RNS was interesting…

“SkinBioTherapeutics finalised commercial terms with Croda following successful additional studies of its skin lysate. The terms include tiered royalties based on global sales revenues on any licensed products derived from the partnership.”

‘ANY licensed products derived from the partnership’. I thought it was interesting it didn’t just say Zenakine, or ‘the licensed product’.

But on the other hand I know if there were any other deals at all in the offing with Croda, SA would have cashed in those brownie points donkeys years ago, so I highly doubt there is anything in it…

Aquae, your message sums up a thought I had whilst reading Bazza’s post where he says he doesn’t rate the CEO. I on the other hand think Stuart Ashman could be a great CEO for SBTX, however it is so frustrating because the facts mean supporting SA isn’t really a debate that can be won at the moment. All the reasons listed by Aquae plus this ridiculous NDA with no end date, and it’s the no end date that is naive of him at best. As someone points out below he should have known how this would play out.

Net, great post with the article, very interesting. The line about the Acne treatment as an aid for mental wellness is very thought provoking. Even if it is not related to Axis, it shows we are well positioned for an upcoming trend.

On the other hand this is all well and good if opportunities are delivered, which we are yet to see. Hopefully the new COO will help SA drive some real world results soon.

I note that four years ago SA was talking about our technology being able to be used as a cleaning product, potentially for home use but also for hospitals which I found extremely exciting. The opportunity being that current products kill all the good bacteria in trying to eradicate MRSA and this makes us sicker as a society over time. The sales of a cleaning product which would solve this problem could surely be hundreds of millions worldwide. I don’t know, because we haven’t been told, but I strongly suspect this has been mostly sidelined over the years trying to launch Axis, deal with Croda etc. I noted the other day that CIF have released a probiotic cleaning product and I couldn’t help but get a sinking feeling that first to market could have been us if it would have been rigorously pursuing the tech. I can’t see how paying people the amounts of Manprit Randhawa and Danielle Bekker is justified but we can not justify 50/60k to pay a project manager to advance these opportunities. Stuart should be managing these people and the big deals, not trying to project manage multiple pillars. Fingers crossed for the new COO though!

Yes it does make you wonder indeed. It will be really odd if the couple of months comes and goes and nothing is said by Stuart Ashman. If it’s not going to be fully lifted it would certainly be wise of him to release a man RNS or even do an IMC, although better an RNS, explaining what the reasons are for the hold up. If it’s because of the assessment of data for more deals then SA could use it as a negotiating tool, and if it’s just because Croda say then I think he needs to stop letting Croda convince him that it would jeopardise the launch. I see why it would have done at the launch, but unless we know otherwise it just looks like the NDA remains in place because ‘they can’.

Nothing wrong with that Toyin, I agree with you completely.

It’s reassuring to see employees of Estée Lauder acknowledging Zenakine. It’s debatable but I’d say liking a post which references such a specific ingredient from a supplier to your employer is only something you would be likely to do if you were working with it.

Good one Dustbin

Sorry, “global sleep science advisor”.

Dustbin101, just to be clear - what you are saying a few posts below is that the Croda post on LinkedIn about Zenakine has been liked by Dr Matthew Walker who has been appointed as Estée Lauder’s sleep advisor?

I know Mol, but don’t let that overshadow the event. Ashman had to pull the trigger and he pulled it. Solid action as required, full stop.

You can imagine the horror he went through as he realised/was told an amendment was required. I like to think he read the body of the RNS multiple times looking for mistakes or anything that could be construed as misleading, keeping it short and to the point. To be let down by the template… i’m gutted for SA but i’m not thinking less of him/them for it.

I am so relieved the future news flow of which there should be a decent bit backing up can be released through the new broker and nomad.

At risk of being the most boring person alive, it’s going to be exciting to see the differences in RNS quality alongside advisors interested in the success of the company and not just lining their own pockets.

Also a great opportunity for SA to review the previous feedback and get that addressed so investors have one less stick to beat him with. Exciting month ahead!

Well done SA. I guess he started the process at the time of the great Cavendish shafting, I suppose these things take time to put into place. Hopefully the new brokers are keen to impress the management and the shareholders. Once again, well done SA.

it’s one thing to create a **** show, it’s another to sit back and watch it for a month. i thought i knew how badly the board were capable of handling the market, turns out i had no idea! i also have no idea how sa is managing to retain his patience with croda, cavendish and others whilst his sp goes to **** and his shareholders get crucified. he must have had a snakes and ladders game as a child from which all the ladders had been stolen!

I’m beginning to liken my investment in SBTX to a big ship in a harbour.

A big, capable vessel which has the potential to regally sail the high seas of the LSE, generating royalties apace, demonstrating own brand product launches which increase sales whilst raising awareness of our exciting science and doing clever new deals progressing passive revenue streams from our IP. A ship the board and the investor base can be really proud of.

Why are we not leaving the harbour Captain Ashman? We are all aboard and there is fuel in the tanks.

> Exclusive UK deal with retailer for Axis set to be announced?

> Does the above mean SA can sign other regional distribution deals covering Rest of World for Axis as originally planned? A juicy vein of RNS material to be tapped into there!

> Announce lifting of Croda NDA. Followed by sales numbers and forecasts to end this ridiculous situation we are in.

> Confirm profitability at PLC level if the above achieves this.

> Update broker forecast.

> Medibiotix deal was close last year and the other party ‘needed to get their house in order which they are doing’; is that close?

> Will Ashman buy some shares when the NDA is lifted?

> Dermatonics update with UMG and NHS sales information.

> Biotech Solutions efficiencies update.

> How is the new COO integrating into the business?

> Are the IMC questions ready to be released?

It’s almost remarkable that the share price is not 30p plus, we just need the CEO to release any sign that he is able to deliver some of the above. We all know he can, but he is clearly starting to fool the market that he is not going to. Come on Stuart!

I think that’s complete nonsense Leapfroggy. The SP has retraced because we know absolutely nothing about figures. The SP has retraced because investors are in the dark. The SP has retraced because of sellers and warrants. Nothing to do with how Croda are marketing the product, which will be for the greatest return on investment. I agree your 40 to 50p could be hit within days of good news and way beyond.

So you’re not sure on the efficacy in cats, Oleric? But, let me guess, you’re going to stick ten grand in anyway and then check the value every single day?

Sky chap, you would think the animal market would be lower barrier to entry than the human market, as SA is always bleeting on about consent, the owner of the animal and purchaser of the product would be able to consent on its behalf. So you might be on to something as a kick starter for that pillar.

I have just watched a you tube video looking for some different information, but in doing so found out that corporation tax on profits from patented products, or royalties derived from patent related products, are only taxed at 10% rather than the usual higher rates of corporation tax.

I realise SBTX has accumulated losses to take advantage of initially but once this is used up, the Skinbiotix pillar should be an extremely tax efficient vehicle for the company over the long term adding shareholder value.

Well Baz, we gave him time to get out of bed… I’ll have to give you that one!

Formulations DireCons, not products, sadly.